Company · JNJ
Johnson & Johnson
Name as listed on its exchange; filed with the SEC as JOHNSON & JOHNSON.
Nasdaq's symbol directory lists JNJ on the New York Stock Exchange as “Johnson & Johnson Common Stock”.
In the 12 months to Nov 8, 2026: insiders sold on 7 occasions ($70.2M); 6 planned-sale notices; 18 congressional trade disclosures; 5 company reports (Form 8-K, since May 26, 2026).
All insider filings at the SEC · Appeared in No. 44, No. 30
Insider trades · SEC Form 4
Those inside the hall
Open-market purchases and sales only. Legs one person filed for one day are combined.
Who traded
- Joaquin Duato, CEO and Chairman of the Board sold $44.7M
- Timothy Schmid, EVP, WW Chair, MedTech sold $9.2M
- Vanessa Broadhurst, EVP, Global Corp Affairs sold $5.8M
- Elizabeth Forminard, EVP, Chief Legal Officer sold $4.1M
- Jennifer L. Taubert, EVP, WWC. Innovative Medicine sold $4.0M
- Kathryn E. Wengel, EVP, Chief TO and Risk Officer sold $2.4M
Every trade (7)
- SELLTimothy Schmid, EVP, WW Chair, MedTech sold $9.2M
- SELLJennifer L. Taubert, EVP, WWC. Innovative Medicine sold $4.0M
- SELLJoaquin Duato, CEO and Chairman of the Board sold $32.2M
- SELLElizabeth Forminard, EVP, Chief Legal Officer sold $4.1M
- SELLJoaquin Duato, CEO and Chairman of the Board sold $12.5M
- SELLVanessa Broadhurst, EVP, Global Corp Affairs sold $5.8M
- SELLKathryn E. Wengel, EVP, Chief TO and Risk Officer sold $2.4M
Planned sales · SEC Form 144
Notice given
A Form 144 is filed before an insider sells restricted stock. It states an intent; the sale, if it happens, appears later on a Form 4. Every recent notice
- Schmid Timothy $9.2M
- Taubert Jennifer L $4.0M
- Duato Joaquin $32.2M
- Forminard Elizabeth $4.1M
- Joaquin Duato $12.4M
- Broadhurst Vanessa $5.8M
Congress · STOCK Act
The Althing
Periodic transaction reports. Amounts are the ranges members report; the trade date is when it happened, the report can come up to 45 days later.
- Thomas H. Kean (R-NJ07): Sale $1,001 - $15,000
- Lloyd Doggett (D-TX37): Purchase $1,001 - $15,000
- Thomas H. Kean (R-NJ07): Sale $1,001 - $15,000
- John Boozman (R-AR): Sale (Partial) $1,001 - $15,000
- Richard Dean Dr McCormick (R-GA06): Sale $1,001 - $15,000
- Thomas H. Kean (R-NJ07): Sale $1,001 - $15,000
- Lloyd Doggett (D-TX37): Purchase $1,001 - $15,000
- Thomas H. Kean (R-NJ07): Sale $1,001 - $15,000
- Alan Armstrong (R-OK): Purchase $1,001 - $15,000
- Alan Armstrong (R-OK): Purchase $15,001 - $50,000
- Thomas H. Kean (R-NJ07): Sale $1,001 - $15,000
- Richard Dean Dr McCormick (R-GA06): Sale $1,001 - $15,000
- John Boozman (R-AR): Sale (Partial) $1,001 - $15,000
- Richard Dean Dr McCormick (R-GA06): Sale $1,001 - $15,000
- Lloyd Doggett (D-TX37): Purchase $1,001 - $15,000
- Thomas H. Kean (R-NJ07): Sale $15,001 - $50,000
- Julie Johnson (D-TX32): Sale $1,001 - $15,000
- Lloyd Doggett (D-TX37): Purchase $1,001 - $15,000
Company reports · SEC Form 8-K
In its own words
Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.
- Results of operations and financial condition Oct 13, 2026
- Departure or appointment of directors or officers Aug 4, 2026
- Regulation FD disclosure Jul 29, 2026
- Regulation FD disclosure Jul 28, 2026
- Results of operations and financial condition Jul 15, 2026
Sources: SEC EDGAR (Forms 4, 144 and 8-K) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.